Designing the Optimal Radiopharmaceutical: Matching Target, Ligand Design, Radionuclide and Disease Biology
11:00 am - Wednesday 2nd December 2026
- Exploring how target biology, ligand properties, radionuclide characteristics and disease context work together to shape radiopharmaceutical performance.
- Examining how molecular design and pharmacokinetics drive biodistribution, tumor retention, normal-organ exposure and ultimately therapeutic index.
- Sharing lessons from next-generation radiopharmaceutical programs on integrating these factors to design differentiated therapies with improved clinical potential.
